Figure 6.

Effects of ERK/p38 MAPK inhibition on pathological phenotypes in APP/PS1 mice. Following oral administration with GGA, WT and APP/PS1 mice were treated with quercetin, SB-203580 or PD98059 to evaluate the involvement of ERK/p38 MAPK signaling in the alleviation of pathological phenotypes in GGA-treated APP/PS1 mice. Levels of soluble (A) Aβ40 and (B) Aβ42 in the brain of WT and APP/PS1 mice were measured by sandwich ELISA. (C) The level of LRP-1 expression was measured by western blotting. ^&P<0.05 vs. untreated WT mice, *P<0.05 vs. untreated Tg mice, ^$P<0.05 vs. Tg+GGA mice. ERK, extracellular signal-regulated protein kinases; p38 MAPK, p38 mitogen-activated protein kinase; APP/PS1, transgenic mouse strain; GGA, geranylgeranylacetone; SB-203580, p38 inhibitor; PD98059, ERK inhibitor; Aβ, amyloid-β; LRP-1, lipoprotein receptor-related protein 1; WT, wild type; Tg, transgenic.